Research

Different cells. Shared questions.

We study how adaptive immune cells sense context, communicate and choose cell fates—and how those decisions can be redirected in disease.

T-cell program

Regulatory T cells where tolerance is decided.

We study how antigen-specific regulatory T cells establish and maintain peripheral tolerance. A central question is how Treg recognition of peptide–MHC on antigen-presenting cells produces precise, local immune suppression rather than indiscriminate inhibition of protective immunity.

Antigen-specific toleranceUsing human Tregs and disease-relevant T-cell receptors to understand the antigenic interactions that restrain autoreactive immune responses.

Treg–APC molecular interactionsDefining the signaling and cell-contact machinery that governs peptide–MHC capture, antigen depletion and suppressive function, including pathways associated with LAG-3.

Neuroimmunology and translationConnecting Treg biology to type 1 diabetes, multiple sclerosis, cancer and the development of more selective tolerance-based therapies.

B-cell program

The logic behind B-cell fate.

We examine how B-cell receptor, innate and metabolic signals are integrated over time to determine whether B cells activate, survive, differentiate or change function. Our goal is to understand the molecular logic inside this cell-fate decision process and how it is altered in disease.

Signaling and cell-fate decisionsDissecting how BCR and Toll-like receptor signals, ion flux and metabolic programs combine over time to control B-cell outcomes.

Immunometabolism and diseaseInvestigating how metabolic environments—including obesity and other disease-associated states—reshape B-cell fitness, differentiation and humoral immunity.

Host–pathogen and vaccine immunityStudying B-cell responses to infection and vaccination, including mechanisms that shape durable antibody responses and host–pathogen interactions.